[
  {
    "ts": "2025-09-22T13:28:00+00:00",
    "headline": "Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?",
    "summary": "DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.",
    "url": "https://finance.yahoo.com/news/quest-diagnostics-stock-pick-portfolio-132800288.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d63e0451-37ac-34e9-900c-cb1507186b4b",
      "content": {
        "id": "d63e0451-37ac-34e9-900c-cb1507186b4b",
        "contentType": "STORY",
        "title": "Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?",
        "description": "",
        "summary": "DGX posts strong gains from physician and hospital channels while advancing AI-powered solutions.",
        "pubDate": "2025-09-22T13:28:00Z",
        "displayTime": "2025-09-22T13:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/quest-diagnostics-stock-pick-portfolio-132800288.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/quest-diagnostics-stock-pick-portfolio-132800288.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CAH"
            },
            {
              "symbol": "DGX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-22T12:49:58+00:00",
    "headline": "Is Quest Diagnostics Stock Underperforming the Dow?",
    "summary": "Although Quest Diagnostics has underperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.",
    "url": "https://www.barchart.com/story/news/34953761/is-quest-diagnostics-stock-underperforming-the-dow",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "79b7055f-4eb5-319e-ba67-cbb3db7b1dee",
      "content": {
        "id": "79b7055f-4eb5-319e-ba67-cbb3db7b1dee",
        "contentType": "STORY",
        "title": "Is Quest Diagnostics Stock Underperforming the Dow?",
        "description": "",
        "summary": "Although Quest Diagnostics has underperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.",
        "pubDate": "2025-09-22T12:49:58Z",
        "displayTime": "2025-09-22T12:49:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/fd1e96fc37af1fb391b6bb273201cf29",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Quest Diagnostics, Inc_ sign- by Sundry Photogreaphy via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WLR5RuBxcYADj.IkVQXDiA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/fd1e96fc37af1fb391b6bb273201cf29.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4.6sy2JFCzandl3XESv.qQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/fd1e96fc37af1fb391b6bb273201cf29.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/34953761/is-quest-diagnostics-stock-underperforming-the-dow",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/quest-diagnostics-stock-underperforming-dow-124958587.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DGX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-22T12:07:00+00:00",
    "headline": "Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer",
    "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensi",
    "url": "https://finance.yahoo.com/news/haystack-oncology-rutgers-cancer-institute-120700314.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "c4257f38-5a80-35de-b51d-46ca2e894012",
      "content": {
        "id": "c4257f38-5a80-35de-b51d-46ca2e894012",
        "contentType": "STORY",
        "title": "Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer",
        "description": "",
        "summary": "Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensi",
        "pubDate": "2025-09-22T12:07:00Z",
        "displayTime": "2025-09-22T12:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b",
          "originalWidth": 400,
          "originalHeight": 190,
          "caption": "Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FuRCtrLWo1T4qYYDhuscJw--~B/aD0xOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b.cf.webp",
              "width": 400,
              "height": 190,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L_XnLitlJHZ7Gn01q1kijg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/328ba769d21514205fa2226e0dacf99b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/haystack-oncology-rutgers-cancer-institute-120700314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/haystack-oncology-rutgers-cancer-institute-120700314.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DGX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]